Sign up to save your podcasts
Or
Share Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy
Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimize outcomes in squamous disease. Upon completion of this activity, participants should be better able to: Assess guideline-based recommendations and biomarker profiles to inform first-line immunotherapy-based treatment selection for squamous NSCLC; Identify clinical factors that may be used to tailor first-line immunotherapy-based approaches across a range of PD-L1 expression levels and patient subtypes; and Recommend long-term, real-world clinical approaches to optimize the risk/benefit profiles of immunotherapy-based treatments in patients with squamous NSCLC.
View all episodes
By Answers in CME
5
77 ratings
Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimize outcomes in squamous disease. Upon completion of this activity, participants should be better able to: Assess guideline-based recommendations and biomarker profiles to inform first-line immunotherapy-based treatment selection for squamous NSCLC; Identify clinical factors that may be used to tailor first-line immunotherapy-based approaches across a range of PD-L1 expression levels and patient subtypes; and Recommend long-term, real-world clinical approaches to optimize the risk/benefit profiles of immunotherapy-based treatments in patients with squamous NSCLC.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Breast Cancer Update
66 Listeners
Research To Practice | Oncology Videos
120 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
11 Listeners
ASCO Daily News
59 Listeners
The Curbsiders Internal Medicine Podcast
3,362 Listeners
The ONS Podcast
203 Listeners
The Daily Show: Ears Edition
14,292 Listeners
OncLive® On Air
22 Listeners
The Clinical Problem Solvers
515 Listeners
Blood Podcast
52 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,909 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
42 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Primary Care
6 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners